PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to
Rule 12b-25(b), the following should be completed. (Check box
if appropriate)
|
ý
|
(a)
|
The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or
expense;
|
|
ý
|
(b)
|
The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly
report of transition report on Form 10-Q or subject distribution
report on Form 10-D, or portion thereof, will be filed on or before
the fifth calendar day following the prescribed due date; and
|
|
☐
|
(c)
|
The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F,
11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion
thereof, could not be filed within the prescribed time
period.
The registrant was not, without unreasonable effort or expense,
able to file its Annual Report on Form 10Q for the period ended
April 30, 2019 . The registrant anticipates that it will file its
Form 10-Q within the "grace" period provided by Securities Exchange
Act Rule 12b-25.
PART IV — OTHER INFORMATION
|
(1)
|
|
Name and telephone number of person to contact in regard to this
notification
|
|
|
|
|
|
|
|
John Verghese
|
|
(727)
|
|
228-3994
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
|
|
|
|
|
|
|
|
(2)
|
|
Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of
the Investment Company Act of 1940 during the preceding
12 months or for such shorter period that the registrant was
required to file such report(s) been filed? If answer is no,
identify report(s).
|
|
|
|
Yes ý
No ☐
|
|
|
|
|
|
(3)
|
|
Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the
subject report or portion thereof?
|
|
|
|
Yes ☐
No ☒
|
|
|
|
|
|
|
|
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be
made.
.
|
Apotheca Biosciences
Inc.
(Name
of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
| |
|
| Date:
June 14, 2019 |
By: /s/ John Verghese |
|
| |
John Verghese |
| |
Chief
Financial Officer |
